Kaletra (Lopinavir/Ritonavir)
Kaletra (Lopinavir/Ritonavir or LPV/RTV) is a protease inhibitor used to treat HIV/AIDS. It is no longer listed in the HHS HIV Treatment Guidelines as a recommended regimen.
Adult Single Dose*: Take 400/100 mg (two 200/50-mg tablets or 5-mL oral solution) twice daily Each tablet contains 400 mg lopinavir and 200 mg ritonavir.
Restrictions:
- Oral solution must be take with food.
- Always take Kaletra in compination with other anti-HIV medicines.
- Women should not breastfeed while on Kaletra.
* This recommendation is for patients starting HIV treatment. A different dose is recommended for treatment experienced patients.
The Basics
- Patient Information About Kaletra (Lopinavir/Ritonavir) Tablets and Oral Solution (PDF) (September 2016)
From AbbVie Inc.
- An Overview of Kaletra (Lopinavir/Ritonavir) (August 23, 2013)
From AIDSinfo
- Lopinavir + Ritonavir (Kaletra) (November 30, 2012)
To read PDF, click here.
From AIDS InfoNet
- Kaletra (March/April 2012)
To read PDF, click here.
In Positively Aware, from Positively Aware
- FAQs About Kaletra (Lopinavir/Ritonavir) (January 12, 2012)
From The Body's "Ask the Experts" Forums
- Medication Guide for Kaletra (February 2011)
Created by the makers of Kaletra specifically for people with HIV. Includes a rundown of possible side effects, reasons why Kaletra may not be a good fit for everybody, meds to avoid while taking Kaletra, and tips on how to maximize the chances Kaletra will work well.
From Abbott Laboratories
- Patient Frequently Asked Questions (2011)
Information about the new Kaletra (lopinavir/ritonavir) tablets.
From Abbott Laboratories
- Kaletra (Lopinavir/Ritonavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- Lopinavir (Kaletra) (August 15, 2006)
From AIDS Treatment Data Network
- Kaletra (Lopinavir/Ritonavir) (November 2005)
To read PDF, click here.
From The Center for AIDS Information & Advocacy
VIEW ALL ARTICLES
News
 Lopinavir/Ritonavir Pellets for Children Tentatively Approved by the FDA (June 2015)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Abbott Cuts Cost of AIDS Drug for Government Programs (May 10, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from CDC National Prevention Information Network
- Abbott Cuts Cost of AIDS Drug for Government Programs (April 29, 2011)
In Chicago Tribune
- Lopinavir/r Oral Solution (March/April 2011)
To read PDF, click here.
In HIV Treatment Bulletin, from HIV i-Base
- U.S. Jury Rejects Glaxo Antitrust Claim vs. Abbott (March 31, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from CDC National Prevention Information Network
- U.S. Warns Against Abbott HIV Drug in Premature Babies (March 9, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from CDC National Prevention Information Network
- Kaletra (Lopinavir/Ritonavir) Oral Solution Label Changes Related to Toxicity in Preterm Neonates (February 24, 2011)
From U.S. Food and Drug Administration
- Once a Day Kaletra Gets Approved for Treatment Experienced, but With Caution (February 2011)
To read PDF, click here.
In Project Inform Perspective, from Project Inform
- Indian Government Rejects Abbott's Patent Application for Second-Line ARV (January 4, 2011)
In Kaiser Daily Global Health Policy Report, from Henry J. Kaiser Family Foundation
- Lopinavir/Ritonavir Approved (Summer/Fall 2010)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation
VIEW ALL ARTICLES
Research
 Slow But Steady Increase in Kidney Risk Observed With TDF, Atazanavir, Lopinavir (August 24, 2016)
From TheBodyPRO.com
 Lopinavir/Ritonavir Superior to Nevirapine in Children Over 3 Years Old: IMPAACT P1060 Study Results (March 24, 2015)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Outcomes in Infants Exposed to Lopinavir/Ritonavir in Utero (February 2014)
In HIV Treatment Bulletin, from HIV i-Base
On TheBodyPRO.com
- Kaletra + Raltegravir: Does Sparing Some Nukes Help Bones? (February 2014)
In TreatmentUpdate, from Canadian AIDS Treatment Information Exchange
On TheBodyPRO.com
 Dual-Drug Therapy of Lopinavir/Ritonavir and Lamivudine Non-Inferior to Triple-Drug Therapy (October 28, 2013)
In The 14th European AIDS Conference (EACS 2013), from TheBodyPRO.com
- Dual Therapy With Kaletra + Lamivudine Works Well Regardless of Viral Load (October 19, 2013)
From HIVandHepatitis.com
- Lopinavir/Ritonavir Monotherapy: The Answer's Still No (August 28, 2013)
In The 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from TheBodyPRO.com
- Lower-Dose Lopinavir/Ritonavir Reduces Side-Effects, Maintains Viral Control in Thai Children (July 9, 2013)
From aidsmap.com
- Low-Dose Lopinavir/RTV Tablet Matches Full Dose in Thai Children (July 6, 2013)
From International AIDS Society
- Low-Dose Drug Combo Safe in Kids With HIV (July 5, 2013)
From MedPage Today
VIEW ALL ARTICLES
|
|
Advertisement
|
Email
Glossary
